Executive Director, Investor Relations

Revolution Medicines

3d•$252,000 - $315,000•Onsite

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director, Investor Relations will serve as a strategic leader responsible for defining, elevating, and executing Revolution Medicines’ global investor relations strategy during a pivotal transition to a commercial-stage organization. This individual will act as a key advisor to senior leadership, helping shape how the company’s evolving clinical, regulatory, and commercial story is communicated to the investment community This role will be instrumental in positioning the company for long-term value creation as it approaches product launches, advances and expands its pipeline, and navigates increasingly complex capital markets dynamics. The Executive Director will lead all aspects of the investor relations function, oversee engagement with the investment community, and ensure the company’s narrative effectively reflects its transition from a development-stage to a commercial-stage enterprise. This position will report to the Senior Vice President of Corporate Affairs and work closely with the CEO and broader executive team. The role will also be responsible for building and leading a high-performing investor relations function.

Requirements

Experienced executive with a strong track record of leadership in investor relations within the biopharmaceutical industry, ideally with experience supporting companies through late-stage development and into commercialization.
Bachelor’s degree required; advanced degree (MBA, PhD, or equivalent) strongly preferred.
10+ years of relevant experience, including progressive leadership experience in investor relations, corporate affairs, or finance within biotech/pharmaceuticals.
Demonstrated experience supporting a company through late-stage clinical development, regulatory milestones, and/or commercial launch.
Deep understanding of capital markets, investor expectations, and valuation drivers for both development-stage and commercial-stage biopharmaceutical companies.
Strong knowledge of clinical development, regulatory pathways, market access, and commercialization strategies.
Proven ability to influence and advise senior executives.
Exceptional communication skills, with the ability to translate complex scientific, clinical, and commercial information into clear, compelling narratives.
Proven experience managing high-profile investor interactions during periods of significant corporate transition.
Strong analytical, strategic, and problem-solving capabilities.
High level of executive presence, credibility, and judgment.
Ability to operate effectively and independently in a fast-paced, dynamic, and evolving organization.

Responsibilities

Accountable for enterprise-level IR strategic planning, long-term external positioning, and integration of IR strategy with broader corporate objectives.
Serve as a spokesperson to the investment community, building trusted relationships with institutional investors, analysts, and key stakeholders.
Advise senior leadership on investor sentiment, market dynamics, and external perception, particularly as the company approaches key inflection points.
Collaborate with Corporate Communications to shape and continuously evaluate the company’s narrative to reflect its evolution, including clear articulation of clinical data, R&D strategy, and commercialization.
Lead the quarterly earnings process and broader financial communications strategy, ensuring messaging reflects both near-term execution and long-term growth potential.
Drive investor targeting and engagement strategies, including conferences, non-deal roadshows, and investor events, with an emphasis on expanding the company’s shareholder base to include high-quality, long-term oriented investors.
Partner cross-functionally with R&D, clinical, regulatory, commercialization, finance, and corporate affairs teams to ensure consistency, accuracy, and strategic alignment of external communications.
Anticipate and proactively address investor questions.
Align investor communications with broader corporate messaging, including ESG strategy and external positioning.
Ensure best practices in disclosure, compliance, and governance as the company’s external visibility and complexity increase.